Literature DB >> 32245098

The Prognostic Value of High Platelet Reactivity in Ischemic Stroke Depends on the Etiology: A Pilot Study.

Adam Wiśniewski1, Karolina Filipska2, Joanna Sikora3, Robert Ślusarz2, Grzegorz Kozera4.   

Abstract

BACKGROUND: Reduced aspirin response may result in a worse prognosis and a poor clinical outcome in ischemic stroke. The aim of this prospective pilot study was to assess the relationship between platelet reactivity and early and late prognosis, and the clinical and functional status in ischemic stroke, with the role of stroke etiology.
METHODS: The study involved 69 subjects with ischemic stroke, divided into large and small vessel etiological subgroups. Platelet function testing was performed with two aggregometric methods-impedance and optical-while the clinical condition was assessed using the National Institute of Health Stroke Scale (NIHSS) and the functional status was assessed using the modified Rankin Scale (mRS) on the first and eighth day (early prognosis) and the 90th day of stroke (late prognosis).
RESULTS: The initial platelet reactivity was found to be higher in patients with severe neurological deficits on the 90th day after stroke, than in the group with mild neurological deficits (median, respectively, 40 area under the curve (AUC) units vs. 25 AUC units, p = 0.033). In the large vessel disease group, a significant correlation between the platelet reactivity and the functional status on the first day of stroke was found (correlation coefficient (R) = 0.4526; p = 0.0451), the platelet reactivity was higher in the subgroup with a severe clinical condition compared to a mild clinical condition on the first day of stroke (p = 0.0372), and patients resistant to acetylsalicylic acid (aspirin) had a significantly greater possibility of a severe neurological deficit on the first day of stroke compared to those who were sensitive to aspirin (odds ratio (OR) = 14.00, 95% confidence interval (CI) 1.25-156.12, p = 0.0322).
CONCLUSION: High on-treatment platelet reactivity in ischemic stroke was associated with a worse late prognosis regardless of the etiology. We demonstrated a significant relationship between high platelet reactivity and worse early prognosis and poor clinical and functional condition in the large vessel etiologic subgroup. However, due to the pilot nature of this study, its results should be interpreted with caution and further validation on a larger cohort is required.

Entities:  

Keywords:  aspirin resistance; carotid stenosis; clinical outcome; ischemic stroke; large vessel disease; platelet reactivity; prognosis

Year:  2020        PMID: 32245098     DOI: 10.3390/jcm9030859

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  4 in total

1.  Platelet-Reactive Antibodies in Patients after Ischaemic Stroke-An Epiphenomenon or a Natural Protective Mechanism.

Authors:  Young Eun Park; Rushi Penumarthy; Paul P Sun; Caroline Y Kang; Marie-Christine Morel-Kopp; Jonathan Downing; Taryn N Green; Tracey Immanuel; Christopher M Ward; Deborah Young; Matthew J During; P Alan Barber; Maggie L Kalev-Zylinska
Journal:  Int J Mol Sci       Date:  2020-11-09       Impact factor: 5.923

Review 2.  The Importance of Platelets Response during Antiplatelet Treatment after Ischemic Stroke-Between Benefit and Risk: A Systematic Review.

Authors:  Joanna Sikora; Aleksandra Karczmarska-Wódzka; Joanna Bugieda; Przemysław Sobczak
Journal:  Int J Mol Sci       Date:  2022-01-18       Impact factor: 5.923

Review 3.  Biomarkers for Antiplatelet Therapies in Acute Ischemic Stroke: A Clinical Review.

Authors:  Adel Alhazzani; Poongothai Venkatachalapathy; Sruthi Padhilahouse; Mohan Sellappan; Murali Munisamy; Mangaiyarkarasi Sekaran; Amit Kumar
Journal:  Front Neurol       Date:  2021-06-10       Impact factor: 4.003

Review 4.  The Phenomenon of Clopidogrel High On-Treatment Platelet Reactivity in Ischemic Stroke Subjects: A Comprehensive Review.

Authors:  Adam Wiśniewski; Karolina Filipska
Journal:  Int J Mol Sci       Date:  2020-09-03       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.